title: Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
abstract: OBJECTIVE
  Tacrine is extensively metabolized by cytochrome P4501A2 (CYP1A2). Fluvoxamine, a potent CYP1A2 inhibitor, may be coadministered with tacrine. The aim of this study was to examine the influence of fluvoxamine administration on the disposition kinetics of single-dose tacrine administration.
  
  
  METHODS
  Thirteen healthy volunteers participated in this double-blind, randomized crossover study, which compared the effects of fluvoxamine (100 mg/day during 6 days) and placebo on the pharmacokinetics of a single oral dose of tacrine (40 mg).
  
  
  RESULTS
  Fluvoxamine caused a significant increase in tacrine area under the plasma concentration versus time curve (AUC): arythmetic mean, 27 (95% confidence interval [CI], 19 to 38) ng.hr/ml versus 224 (95% CI, 166 to 302) ng. hr/ml. Fluvoxamine caused a decrease in the apparent oral clearance of tacrine from 1683 +/- 802 to 200 +/- 106 L/hr (mean +/- SD), which was explained by a decrease in its nonrenal clearance. Five subjects had gastrointestinal side effects during fluvoxamine administration. Fluvoxamine administration was associated with significant increases in the plasma AUC values of three monohydroxylated tacrine metabolites and in the total urinary recovery measurements of tacrine and its metabolites (9.1% +/- 4.6% versus 24.0% +/- 2.6% of recovery). These results may be attributable to fluvoxamine-dependent inhibition of CYP1A/, which is responsible of the biotransformation of tacrine into its monohydroxylated metabolites and further into dihydroxylated and reactive metabolites.
  
  
  CONCLUSIONS
  Fluvoxamine inhibits the metabolism of tacrine. CYP1A2 may be the target of this inhibition. Fluvoxamine may modulate the hepatotoxicity of tacrine, depending on the relative contribution of tacrine and its reactive metabolites to this toxicity.
authors.affiliation: Clinical Pharmacology Unit, Saint Antoine University Hospital, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Becquemont
authors.forename: I
authors.initials: I
authors.lastname: Ragueneau
authors.forename: M A
authors.initials: MA
authors.lastname: Le Bot
authors.forename: C
authors.initials: C
authors.lastname: Riche
authors.forename: C
authors.initials: C
authors.lastname: Funck-Brentano
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D000328:Adult; D019540:Area Under Curve; D002800:Cholinesterase Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D018592:Cross-Over Studies; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D004311:Double-Blind Method; D016666:Fluvoxamine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D012016:Reference Values; D012044:Regression Analysis; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013619:Tacrine / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D002800:Cholinesterase Inhibitors; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; D013619:Tacrine